Skip to main content
Clinical Trials/JPRN-jRCT1031210377
JPRN-jRCT1031210377
Active, not recruiting
未知

Change in quality of life in the treatment change from 5-day treatment to patient-initiated therapy of anti-herpesvirus drugs in patients with recurrent herpes simplex -Exploratory prospective observational study- - Q-pid study

Hayakawa Jun0 sites100 target enrollmentOctober 14, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Recurrent herpes simplex
Sponsor
Hayakawa Jun
Enrollment
100
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 14, 2021
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Hayakawa Jun

Eligibility Criteria

Inclusion Criteria

  • (1\) Male or female Japanese subjects, \>\=20 years old at the time of signing informed consent
  • (2\) Subjects who may recur herpes simplex three times or more per year
  • (3\) Subjects who can recognize the early symptoms of recurrent herpes simplex (a feeling of strangeness, burning or itching, etc)
  • (4\) Subjects who had the early symptoms of herpes simplex or skin rashes for 72 hours or longer
  • (5\) Subjects who received the oral anti\-herpesvirus agents for 5 days and wish to receive the PIT (patient\-initiated therapy) at the next recurrence of herpes simplex

Exclusion Criteria

  • (1\)Any known history of hypersensitivity to the excipient (famciclovir) of the research drug
  • (2\)Subjects whose immune response may decrease due to hematopoietic stem cell transplantation, organ transplantation or HIV (human immunodeficiency virus) infection
  • (3\) A person who has participated in a clinical study of a vaccine for herpes simplex or herpes zoster.
  • (4\) Persons who have participated in clinical research, clinical trials, or post\-marketing clinical trials of therapeutic agents for herpes simplex or herpes zoster during the 6 months prior to the date of consent.
  • (5\) Those who are participating or have participated in other clinical research, clinical trials or post\-marketing clinical trials other than (3\) or (4\) within 4 months prior to the date of consent.
  • (6\)Pregnant women, women of child\-bearing potential, or lactating women
  • (7\)Subjects or his/her partner who will not use adequate contraceptive methods between the time of signing informed consent and the completion of the research
  • (8\)Subjects who have received suppressive treatment for herpes simplex within 6 months before signing informed consent
  • (9\)Subjects who are ineligible to participate in this research by the consideration of the principal researcher or sub\-researcher

Outcomes

Primary Outcomes

Not specified

Similar Trials